Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$72.01

6.01 (9.11%)

, IONS

Ionis Pharmaceuticals

$44.94

1.04 (2.37%)

06:37
05/17/17
05/17
06:37
05/17/17
06:37

Alnylam price target raised to $80 from $75 at Ladenburg

Ladenburg Thalmann analyst Christopher James raised his price target for Alnylam (ALNY) to $80 saying the NEURO-TTR data reported by Ionis Pharmaceuticals (IONS) are "quite positive" for patisiran and the upcoming APOLLO readout. The analyst reiterates a Buy rating on Alnylam shares.

ALNY

Alnylam

$72.01

6.01 (9.11%)

IONS

Ionis Pharmaceuticals

$44.94

1.04 (2.37%)

  • 18

    May

  • 22

    May

  • 24

    May

  • 06

    Jun

ALNY Alnylam
$72.01

6.01 (9.11%)

05/16/17
PIPR
05/16/17
NO CHANGE
Target $69
PIPR
Overweight
Piper Jaffray sees positive readthrough for Prothena from Ionis data
Piper Jaffray analyst Steven Breazzano argues that investors should "take a closer look" at Prothena (PRTA) and its PRX004 product following the recent amyloid neuropathy data from Ionis Pharmaceuticals (IONS). Prothena's candidate is expected to enter the clinic in early 2018, and Breazzano argues that there is "room for differentiation" in the space, as the drug clears the protein buildup that characterizes amyloidosis rather than directly shutting off production, as with Ionis and Alnylam's (ALNY) approaches. "At a minimum," the analyst says, a deposit-clearing approach would be complementary to production-stopping drugs. Breazzano reiterates an Overweight rating on Prothena.
05/16/17
LEER
05/16/17
NO CHANGE
Target $67
LEER
Outperform
Alnylam price target raised to $67 from $53 at Leerink
Leerink analyst Paul Matteis expects yesterday's data from Ionis Pharmaceuticals (IONS) will put TTRrx at a commercial disadvantage to Alnylam's (ALNY) patisiran. The top-line results for TTRrx, which showed high efficacy and several safety issues, is the best case for Alnylam, Matteis tells investors in a research note. He raised his odds of approval for both programs but lowered his price target for Ionis to $45 from $47. Matteis has Market Perform ratings on both stocks.
05/16/17
FBCO
05/16/17
NO CHANGE
Target $90
FBCO
Outperform
Alnylam price target raised to $90 after Ionis data at Credit Suisse
Credit Suisse analyst Alethia Young said her conviction that Alnylam (ALNY) will be successful in its Phase 3 familial amyloid polyneuropathy trial has been increased following the data reported by competitor Ionis (IONS). She is also adjusting her market share estimates for their two FAP drugs, modeling the market split to be 70% in favor of Alnylam's patisiran and 30% for Ionis' inotersen, as she believes patisiran will have a better safety profile. Young raised her price target on Alnylam shares to $90 from $50 and keeps an Outperform rating on the stock, which gained 16% yesterday to close at $66.
05/15/17
CHDN
05/15/17
NO CHANGE
Target $110
CHDN
Buy
Alnylam price target raised to $110 from $95 at Chardan
IONS Ionis Pharmaceuticals
$44.94

1.04 (2.37%)

05/16/17
RHCO
05/16/17
NO CHANGE
RHCO
Prothena has positive read through from Ionis safety issues, says SunTrust
SunTrust analyst Yun Zhong says that safety issues with Ionis' inotersen during a Phase III trial are positive for Prothena. The analyst says that Prothena's new drug, PRX004, could have a better safety profile than its previous drug, NEOD001,. He notes that PRX004 has a different mechanism of action than Ionis' drug, and he thinks the discrepancy could enable Prthena's drug to have a better safety profile. He keeps a Buy rating on Prothena.

TODAY'S FREE FLY STORIES

EXAS

Exact Sciences

$32.65

-0.67 (-2.01%)

, UNH

UnitedHealth

$176.59

-0.91 (-0.51%)

07:31
05/31/17
05/31
07:31
05/31/17
07:31
Recommendations
Exact Sciences, UnitedHealth analyst commentary  »

Exact Sciences remains a…

EXAS

Exact Sciences

$32.65

-0.67 (-2.01%)

UNH

UnitedHealth

$176.59

-0.91 (-0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 31

    May

  • 06

    Jun

QCOM

Qualcomm

$57.34

-0.18 (-0.31%)

, NXPI

NXP Semiconductors

$108.14

0.14 (0.13%)

07:31
05/31/17
05/31
07:31
05/31/17
07:31
Hot Stocks
Qualcomm extends cash tender offer for NXP Semiconductors outstanding shares »

Qualcomm (QCOM) announced…

QCOM

Qualcomm

$57.34

-0.18 (-0.31%)

NXPI

NXP Semiconductors

$108.14

0.14 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

  • 09

    Jun

FRO

Frontline

$5.41

-0.22 (-3.91%)

07:31
05/31/17
05/31
07:31
05/31/17
07:31
Upgrade
Frontline rating change  »

Frontline upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGHT

8x8, Inc.

$13.60

0.1 (0.74%)

07:30
05/31/17
05/31
07:30
05/31/17
07:30
Conference/Events
8x8, Inc. management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 01

    Jun

  • 06

    Jun

  • 06

    Jun

  • 08

    Jun

  • 13

    Jun

GNRT

Gener8 Maritime

$4.91

0.06 (1.24%)

, FRO

Frontline

$5.41

-0.22 (-3.91%)

07:30
05/31/17
05/31
07:30
05/31/17
07:30
Recommendations
Gener8 Maritime, Frontline, DHT Holdings analyst commentary  »

Gener8 Maritime advance…

GNRT

Gener8 Maritime

$4.91

0.06 (1.24%)

FRO

Frontline

$5.41

-0.22 (-3.91%)

DHT

DHT Holdings

$4.20

-0.07 (-1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$7.28

-0.69 (-8.66%)

, ORCL

Oracle

$45.42

0.16 (0.35%)

07:30
05/31/17
05/31
07:30
05/31/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

WLL

Whiting Petroleum

$7.28

-0.69 (-8.66%)

ORCL

Oracle

$45.42

0.16 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KORS

Michael Kors

$36.27

-0.49 (-1.33%)

07:25
05/31/17
05/31
07:25
05/31/17
07:25
Technical Analysis
Technical View: Michael Kors drops to new 52-week low after earnings »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

CBS

CBS

$61.52

-0.05 (-0.08%)

, CBS.A

$63.50

-0.15 (-0.24%)

07:24
05/31/17
05/31
07:24
05/31/17
07:24
Periodicals
Scott Pelley to depart anchor role on 'CBS Evening News,' NY Times says »

CBS (CBS, CBS.A) news…

CBS

CBS

$61.52

-0.05 (-0.08%)

CBS.A

$63.50

-0.15 (-0.24%)

CMCSA

Comcast

$41.10

0.19 (0.46%)

CMCSK

Comcast

DIS

Disney

$108.34

-0.07 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

  • 08

    Jun

  • 15

    Jun

KORS

Michael Kors

$36.27

-0.49 (-1.33%)

07:23
05/31/17
05/31
07:23
05/31/17
07:23
Hot Stocks
Breaking Hot Stocks news story on Michael Kors »

Michael Kors drops 7% in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

UAA

Under Armour

$19.56

-0.13 (-0.66%)

07:23
05/31/17
05/31
07:23
05/31/17
07:23
Recommendations
Under Armour analyst commentary  »

Under Armour has reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

07:22
05/31/17
05/31
07:22
05/31/17
07:22
General news
Futures higher ahead of final trading for May »

Stock futures are above…

KORS

Michael Kors

$36.27

-0.49 (-1.33%)

07:22
05/31/17
05/31
07:22
05/31/17
07:22
Hot Stocks
Michael Kors says to close 100-125 full-price retail stores over next two years »

Michael Kors announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

MYL

Mylan

$39.36

-0.36 (-0.91%)

07:19
05/31/17
05/31
07:19
05/31/17
07:19
Recommendations
Mylan analyst commentary  »

Pension fund campaign a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

  • 09

    Oct

VIAB

Viacom

$35.05

-0.08 (-0.23%)

, VIA

Viacom

$38.90

0.5 (1.30%)

07:17
05/31/17
05/31
07:17
05/31/17
07:17
Recommendations
Viacom, Viacom analyst commentary  »

Viacom price target…

VIAB

Viacom

$35.05

-0.08 (-0.23%)

VIA

Viacom

$38.90

0.5 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XXII

22nd Century

$1.37

-0.02 (-1.44%)

07:17
05/31/17
05/31
07:17
05/31/17
07:17
Hot Stocks
22nd Century reports 'dramatic surge' in VLN tobacco clinical trials, science »

22nd Century Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABT

Abbott

$45.00

0.29 (0.65%)

07:16
05/31/17
05/31
07:16
05/31/17
07:16
Recommendations
Abbott analyst commentary  »

Abbott making progress, …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRMN

Garmin

$52.11

-0.29 (-0.55%)

07:15
05/31/17
05/31
07:15
05/31/17
07:15
Hot Stocks
Garmin launches Approach S60 golf watch »

Garmin International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLCA

U.S. Silica

$36.45

-0.76 (-2.04%)

07:15
05/31/17
05/31
07:15
05/31/17
07:15
Technical Analysis
Technical View: U.S. Silica trades higher in pre-market »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

GPRK

GeoPark

$8.71

-0.18 (-2.02%)

07:12
05/31/17
05/31
07:12
05/31/17
07:12
Hot Stocks
GeoPark names Coulter Enterprises Chairman and CEO Coulter to board »

GeoPark Limited announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRQR

ProQR Therapeutics

$4.70

-0.3 (-6.00%)

07:12
05/31/17
05/31
07:12
05/31/17
07:12
Hot Stocks
ProQR Therapeutics' QR-110 granted Fast Track designation by FDA »

ProQR Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$66.30

-0.57 (-0.85%)

07:11
05/31/17
05/31
07:11
05/31/17
07:11
Downgrade
Molina Healthcare rating change  »

Molina Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSK

GlaxoSmithKline

$43.41

0.74 (1.73%)

07:11
05/31/17
05/31
07:11
05/31/17
07:11
Technical Analysis
Technical View: GlaxoSmithKline rises in early trading »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

RGNX

Regenxbio

$16.70

-1.3 (-7.22%)

07:09
05/31/17
05/31
07:09
05/31/17
07:09
Earnings
Regenxbio initiates Phase 1 clinical trial of RGX-314 for macular degeneration »

Regenxbio has dosed the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$130.49

-3.89 (-2.89%)

07:08
05/31/17
05/31
07:08
05/31/17
07:08
Recommendations
Incyte analyst commentary  »

Incyte price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 13

    Jun

  • 15

    Jun

TRIL

Trillium Therapeutics

$5.05

0.05 (1.00%)

07:08
05/31/17
05/31
07:08
05/31/17
07:08
Hot Stocks
Trillium to present TTI-621 immune checkpoint inhibitor program at ASCO »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.